Pay in 4 interest-free payments of $5.11 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Stay tuned for more learnings coming out of the Omada Insights Lab, through our new ANSWERS Initiative, whose next planned project will examine real-world evidence on the effectiveness of the Omada program on weight maintenance following GLP-1 discontinuation.
Morgan Wealth ManagementNew YorkNew York - NYC (High Net Worth)$250K$351M$1-10M$250K-1MEdmund DeblerMorgan Stanley Wealth ManagementNew YorkNew York - NYC (High Net Worth)$2M$2.2B$5-25M$20MPhil Di PernaCiti Personal Wealth ManagementNew YorkNew York - NYC (High Net Worth)$250K$341M$750K-2.3M$1.1-3.1MProfile SpotlightJack von MaurJ.P
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence
Comparative dual- versus triple-agonist pharmacology, run alongside GLP-1 (Sema) (single) and GLP-2 (Triz) (dual) to dissect receptor-specific effects
US$ 27.27
US$ 24.44
US$ 28.34
US$ 25.28
US$ 23.68
US$ 26.32
US$ 27.67
US$ 24.17
US$ 23.87
